

BIG3 siRNA (h): sc-95585

BACKGROUND

KIAA1244, also known as ARFGEF3 and BIG3 is a 2,177 single-pass membrane protein that contains one SEC7 domain. KIAA1244 is post-translationally phosphorylated at serine residues 1,651 and 1,991. The gene encoding KIAA1244 maps to human chromosome 6, which contains around 1,200 genes within 170 million base pairs of sequence and comprises nearly 6% of the human genome. Deletion of a portion of the q arm of chromosome 6 is associated with early onset intestinal cancer, suggesting the presence of a cancer susceptibility locus. Porphyria cutanea tarda is associated with chromosome 6 through the HFE gene which, when mutated, predisposes an individual to developing this porphyria. Notably, the PARK2 gene, which is associated with Parkinson's disease, and the genes encoding the major histocompatibility complex proteins, which are key molecular components of the immune system and determine predisposition to rheumatic diseases, are also located on chromosome 6. Stickler syndrome, 21-hydroxylase deficiency and maple syrup urine disease are also associated with genes on chromosome 6. A bipolar disorder susceptibility locus has been identified on the q arm of chromosome 6.

REFERENCES

1. Brunner, H.G., van Beersum, S.E., Warman, M.L., Olsen, B.R., Ropers, H.H. and Mariman, E.C. 1994. A Stickler syndrome gene is linked to chromosome 6 near the COL11A2 gene. *Hum. Mol. Genet.* 3: 1561-1564.
2. Nakajima, D., Okazaki, N., Yamakawa, H., Kikuno, R., Ohara, O. and Nagase, T. 2002. Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones. *DNA Res.* 9: 99-106.
3. Cesari, R., Martin, E.S., Calin, G.A., Pentimalli, F., Bichi, R., McAdams, H., Trapasso, F., Drusco, A., Shimizu, M., Masciullo, V., D'Andrilli, G., Scambia, G., Picchio, M.C., Alder, H., Godwin, A.K. and Croce, C.M. 2003. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. *Proc. Natl. Acad. Sci. USA* 100: 5956-5961.
4. Bläker, H., Mechttersheimer, G., Sutter, C., Hertkorn, C., Kern, M.A., Rieker, R.J., Penzel, R., Schirmacher, P. and Kloor, M. 2008. Recurrent deletions at 6q in early age of onset non-HNPCC- and non-FAP-associated intestinal carcinomas. Evidence for a novel cancer susceptibility locus at 6q14-q22. *Genes Chromosomes Cancer* 47: 159-164.
5. Daub, H., Olsen, J.V., Bairlein, M., Gnad, F., Oppermann, F.S., Körner, R., Greff, Z., Keri, G., Stemmann, O. and Mann, M. 2008. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. *Mol. Cell* 31: 438-448.
6. Fan, J., Ionita-Laza, I., McQueen, M.B., Devlin, B., Purcell, S., Faraone, S.V., Allen, M.H., Bowden, C.L., Calabrese, J.R., Fossey, M.D., Friedman, E.S., Gyulai, L., Hauser, P., Ketter, T.B., Marangell, L.B., Miklowitz, D.J., et al. 2010. Linkage disequilibrium mapping of the chromosome 6q21-22.31 bipolar I disorder susceptibility locus. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 153B: 29-37.
7. Jalil, S., Grady, J.J., Lee, C. and Anderson, K.E. 2010. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. *Clin. Gastroenterol. Hepatol.* 8: 297-302, 302.e1.

CHROMOSOMAL LOCATION

Genetic locus: ARFGEF3 (human) mapping to 6q23.3.

PRODUCT

BIG3 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see BIG3 shRNA Plasmid (h): sc-95585-SH and BIG3 shRNA (h) Lentiviral Particles: sc-95585-V as alternate gene silencing products.

For independent verification of BIG3 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-95585A, sc-95585B and sc-95585C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

BIG3 siRNA (h) is recommended for the inhibition of BIG3 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor BIG3 gene expression knockdown using RT-PCR Primer: BIG3 (h)-PR: sc-95585-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.